Nature Reviews Neurology

Papers
(The H4-Index of Nature Reviews Neurology is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Serum NfL as an MS biomarker334
Reply to: Questioning the cycad theory of Kii ALS–PDC causation322
Olfactory network function altered in COVID-19287
Long-term safety of satralizumab in NMOSD219
Sodium channelopathy could underlie concussion symptoms213
Reply to: Neuroimmune interactions and COVID-19 in lung transplant recipients192
Reply to: Assessing prospective memory beyond experimental tasks189
Cortical blood flow associated with cognitive decline in REM sleep behaviour disorder183
Insight into molecular mechanisms of resistance against prion strains173
AI and deep brain stimulation: what have we learned?161
Fatty acids might slow ALS progression159
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma155
α-Crystallin B autoimmunity and multiple sclerosis149
Brain stimulation aids walking after spinal injury146
John Q. Trojanowski143
Are guidelines a useful tool for improving outcomes in neurology?140
Headache in people with epilepsy138
Can we learn lessons from the FDA’s approval of aducanumab?134
Does antiherpetic antiviral therapy reduce the risk of dementia?133
Remyelination stops degeneration in MS124
Inflammasome insight in tauopathies112
Rapid AQP4-IgG detection in neuromyelitis optica spectrum disorder108
The murky waters of sex differences in post-stroke cognitive impairment107
Twin study probes non-heritable immune aspects of multiple sclerosis106
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response102
High rate of epilepsy in young individuals who died with COVID-1997
Deep learning distinguishes tauopathies96
Microscopic blood–brain barrier permeability in reversible cerebral vasoconstriction syndrome95
GluA2 modulator targets excitotoxicity in MS94
Operationalizing the clinical staging scheme in the 2018 NIA–AA research framework89
‘On-demand’ gene therapy for epilepsy86
Refining oxytocin therapy for autism: context is key82
Towards the era of biological biomarkers for Parkinson disease81
Identifying molecular targets in trigeminal nociception81
Multiple sclerosis relapses not associated with mRNA COVID-19 vaccine77
A promising new therapy for ALS76
Neurogenesis altered in multiple neurodegenerative diseases76
Microglia, spreaders of Aβ seeds75
New blood biomarker of refractory epilepsy74
Reply to ‘Cognitive criteria in HIV: greater consensus is needed’74
Transmembrane protein interacts with α-synuclein to confer risk of PD71
TNF — a potential therapeutic target for ALS71
APOE4 provokes tau aggregation via inhibition of noradrenaline transport70
Ventricular enlargement caused by aducanumab70
A biomarker for mild cognitive impairment69
Skin α-synuclein differentiates synucleinopathies69
Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology69
Finger-prick blood test for Alzheimer disease63
BCAS1+ oligodendrocytes aid remyelination in MS63
Engineered T cells show therapeutic potential for CNS injury62
Daily step count linked to dementia risk61
MRI predicts cognitive training effects in multiple sclerosis53
Prodromal psychiatric symptoms in MS53
0.088303089141846